肿瘤药学2018，Vol.8Issue(1)：64-68,83,6.DOI:10.3969/j.issn.2095-1264.2018.01.15
晚期肺腺癌组织中MICA/B的表达变化及其临床意义
The Clinical Study of MICA/B on the Clinicopathological Features and Prognosis of Patients with Advanced Lung Adenocarcinoma
摘要
Abstract
Objective To detect the expression of the major histocompatibility complex class I-related chain A and B (MICA/B) in advanced lung adenocarcinoma tissues and analyze its relationships with patients'clinicopathological features and prognosis. Methods 126 patients with advanced lung adenocarcinoma were immunohistochemically assayed for their expression of MICA/B in advanced lung adenocarcinoma tissues. A total staining scores of <3 or ≥3 were expressed negatively or positively respectively. Relationships of expres-sion of MICA/B with clinicopathological features (EGFR genotyping) and prognosis were analyzed by using the χ2test and the Cox model respectively. Results The positive rate of MICA/B was 48.41% for advanced lung adenocarcinoma tissues. The positive rates were no statis-tical significance among patients with different ages and genders (P>0.05); the differences were statistically significant in patients with dif-ferent TNM stages, T stages, histological grades, lymph node metastasis, and epidermal growth factor receptor (EGFR) genotypes (P<0.05). Survival analysis showed that the survival rate of patients was lower in positive patients than that in negative ones (P<0.05). Histologyical grading, EGFR genotyping, and expression intensity of MICA/B (β=0.642, HR=3.058) were independent influencing factors for patients with advanced lung adenocarcinoma (P<0.05). Conclusion MICA/B,high expression in tissue of advanced lung adenocarcinoma,has a close relationship with TNM stages, T stages, histological grades, lymph node metastasis and EGFR genotypes. It will be a promising auxiliary in-dicator for the evaluation and prognosis judgment of patients with advanced lung adenocarcinoma.关键词
非小细胞肺癌/MICA/B/生存期/TNM分期/T分期Key words
Non-small cell lung cancer/MICA/B/Total survival/TNM staging/T staging/Histological grading分类
医药卫生引用本文复制引用
王佳佳,梅家转,赵继智,冯睿婷,张世魁,徐虹..晚期肺腺癌组织中MICA/B的表达变化及其临床意义[J].肿瘤药学,2018,8(1):64-68,83,6.基金项目
郑州市科技计划项目(121PLJRC532). （121PLJRC532）
